PRESS INFORMATION BUREAU
पत्र सूचना कार्यालय
GOVERNMENT OF INDIA
भारत सरकार

MINT, Delhi
Wednesday 4th June 2014, Page: 11
Width: 5.02 cms, Height: 8.98 cms, a4, Ref: pmin.2014-06-04.50.60

CORPORATE

Aurobindo gets FDA nod to market drug

New Delhi: Aurobindo Pharma Ltd has received US health regulator's approval to market generic version of **AbbVie Inc.**'s Depakote ER extended-release tablets, used for treating mental illness, in the American market.

The company has received final approval from US Food and Drug Administration (FDA) to manufacture and market divalproex sodium extended-release tablets in strengths of 250mg and 500mg, Aurobindo Pharma said in a statement on Tuesday.

The Hyderabad-based firm said the "product is ready for launch". Divalproex sodium extended-release tablets are indicated for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features. **PTI**

Company